Skip to main content

Table 1 Baseline demographic and clinical characteristics of study participants

From: A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

 

Total

N = 39

Group 1

N = 12

Group 2

N = 12

Group 3

N = 3

Group 4

N = 12

Age (years)

20

21

20

20

20

Median

     

(IQR)

(20–1)

(20–21)

(20–21)

(19–20)

(20–22.5)

BMI

19.4

18.7

19.5

19.1

20.0

Median

     

(IQR)

(18.3–20.3)

(17.9–0.3)

(18.4–20.2)

(18.3–21.6)

(18.4–20.7)

QFT test

N/A

Negative

Negative

Negative

Positive

(IU/ml)

 

0.011

0.038

0.083

11.8

  1. BMI Body Mass Index, IQR interquartile range, QFT QuantiFERON-TB Gold-in-tube test